Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 14/20 | 0.82 |
| ▸ | KDR | P35968 | 5/20 | 0.75 |
| ▸ | KIT | P10721 | 5/20 | 0.75 |
| ▸ | EGFR | P00533 | 2/20 | 0.74 |
| ▸ | JAK3 | P52333 | 1/20 | 0.74 |
| ▸ | BTK | Q06187 | 1/20 | 0.74 |
| ▸ | ITK | Q08881 | 1/20 | 0.74 |
| ▸ | ABL1 | P00519 | 9/20 | 0.68 |
| ▸ | BCR | P11274 | 6/20 | 0.68 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.68 |
| ▸ | PRKCA | P17252 | 1/20 | 0.66 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.63 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.63 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11927817 | 0.95 | PDGFRA (0.92) | PDGFRAKDRKITEGFRJAK3 | |
| SCHEMBL11927826 | 0.91 | PDGFRA (0.87) | PDGFRAKDRKITEGFRJAK3 | |
| SCHEMBL2317193 | 0.90 | PDGFRA (1.00) | PDGFRAKDRKITEGFRJAK3 | |
| SCHEMBL5050327 | 0.88 | PDGFRA (0.89) | PDGFRAKDRKITEGFRJAK3 | |
| SCHEMBL12627018 | 0.88 | PDGFRA (0.91) | PDGFRAKDRKITEGFRJAK3 | |
| SCHEMBL11927816 | 0.87 | PDGFRA (0.94) | PDGFRAKDRKITEGFRJAK3 | |
| SCHEMBL14979766 | 0.86 | MAPK8 (0.84) | PDGFRAKDRKITEGFRABL1 | |
| SCHEMBL29644765 | 0.86 | MAPK8 (0.84) | PDGFRAKDRKITEGFRABL1 | |
| SCHEMBL11927765 | 0.86 | PDGFRA (1.00) | PDGFRAKDRKITEGFRJAK3 | |
| SCHEMBL14979762 | 0.86 | EGFR (0.77) | PDGFRAKDRKITEGFRJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153730-A9 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-20210300911-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| US-10981903-B2 | Inhibitors of c-Jun-N-terminal kinase (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200087295-A9 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-03-19 | — | — | US | disclosed |
| EP-3569598-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | Dana Farber Cancer Institute, Inc. (US) | 2019-11-20 | — | — | EP | disclosed |
| US-20190248778-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-15 | — | — | US | disclosed |
| EP-2822935-B1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA FARBER CANCER INST INC (US) | 2019-05-15 | — | — | EP | disclosed |
| US-20160368910-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-12-22 | — | — | US | disclosed |
| WO-2013074986-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981903-B2 | Inhibitors of c-Jun-N-terminal kinase (JNK) | CNKSR1, MAPK1, MAP3K1 | PDGFRA 2050/4885KDR 2343/4885KIT 3383/4885 |
| US-20210300911-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | CNKSR1, MAPK1, MAP3K1 | PDGFRA 2050/4885KDR 2343/4885KIT 3383/4885 |
| US-20200087295-A9 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | CNKSR1, MAPK1, MAP3K1 | PDGFRA 2050/4885KDR 2343/4885KIT 3383/4885 |
| US-20220153730-A9 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | CNKSR1, MAPK1, MAP3K1 | PDGFRA 2050/4885KDR 2343/4885KIT 3383/4885 |
| US-20160368910-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | CNKSR1, MAPK1, MAP3K1 | PDGFRA 2050/4885KDR 2343/4885KIT 3383/4885 |
| US-20190248778-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | CNKSR1, MAPK1, MAP3K1 | PDGFRA 2050/4885KDR 2343/4885KIT 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.